Member Info for Wiggly

My own take would be that production must be at the low end of guidance (or lower) otherwise, with oil trading >$100, the share price would be trading at multiples of 24p.

We should not be surprised that there is interest. AS confirmed there was huge interest from big pharma prior to DE.... the interest will only be increasing as each day passes. The fact AS remains as cool as a cucumber regarding future finance options (and does not feel the need to support the current share price) suggests to me that a license deal for AVA6k (and perhaps the entire Precision platform) is close to being inked (prior to PK data release).

Blackcat - yes, I believe they can...

..

Can you imagine progressing the AVA6k trial to the DE stage in the knowledge that the early data was not only 'poor' but also 'remarkably consistent'

Good to know I am not the only holder keeping faith! These guys have much more to lose than I do!

Significant Shareholdings (as of Feb 2022)

Premier Miton Group – 4.66%

Baillie Gifford & Co Limited – 4.63%

Conifer Management, LLC – 2.99%

Deserves its on thread. Hopefully an area to discuss, trade insight and information related to this deal.

It was Sep 21 we last heard of the LG Chem deal. At this point, LG Chem had successfully completed certain pre-clinical in-vivo models in the PD-L1/XT programme leading to the selection of a pre-clinical candidate for further development towards the clinic and triggering an undisclosed milestone payment.

As of March 22, LG Chem still list Avacta as a key partner on their website (link below), which is quite significant when you consider that LG Chem are number 4 in the Top 10 most valuable brands globally.

If we examine the LG pre clinical pipeline (link below), do we know which disease area / code could be linked to Avacta's PD-L1 inhibitor with Affimer XT® serum half-life extension?

https://innovation.lgchem.com/ResearchDevelopment/Pipeline.do

https://www.lgchem.com/upload/file/introduce/2022_Introduction_of_LGChem_en_homepage.pdf

From their website....(innovative platform technologies & targeted treatments - sound familiar?)

LG Chem is committed to developing novel immuno-oncology therapies leveraging innovative platform technologies and targeted treatments. LG Chem is building a global team to reach patients worldwide and bring those therapies to those that need them the most. LG Chem is investing in open innovation to augment their solutions to identify new anti-cancer agents.

Across all therapeutic areas, LG Chem is open to discovering and developing disruptive platform technologies that can fundamentally change how we provide therapeutic solutions in the future.

Beinthelead - why no mention of LG Chem? THe next piece of news related to LG CHem could be explosive...

A1invest - agree.

The deal with LG Chem is a potential company maker and so far all seems to be going well (LG deal expanded during August 2020... amazing how time flies). A LOT can happen over period 18+ months and news must be due soon.

The expansion of the partnership includes an undisclosed additional upfront payment, plus near-term pre-clinical milestones and longer-term clinical development milestones totaling $98.5m for two therapeutics to be developed using the Affimer XT technology. Under the terms of the extended agreement, LG Chem has the exclusive rights to develop and commercialise, on a world-wide basis, Avacta's Affimer PD-L1 inhibitor with Affimer XT serum half-life extension.

The expanded partnership also provides LG Chem with rights to develop and commercialise other Affimer and non-Affimer biotherapeutics combined with Affimer XT half-life extension for a range of indications and Avacta could earn up to $55m in milestone payments for each of these new products.

Many are painting this as an all or nothing on AVA6k however it is far from it.

https://www.bbc.com/news/world-europe-60551140

"Putin's in a tight spot," believes Moscow-based defence analyst Pavel Felgenhauer. "He doesn't have many options left, once the West freezes the assets of the Russian Central bank and Russia's financial system actually implodes. That will make the system unworkable.

"One option for him is to cut gas supplies to Europe, hoping that will make the Europeans climb down. Another option is to explode a nuclear weapon somewhere over the North Sea between Britain and Denmark and see what happens."

I think there is a reason our CEO remains fairly silent. If he had any fear regarding future funding he would be ramping all of the recent positive news.

There is, I am sure, lots of discussions on-going with existing and potential partners related to all aspects of the company.

While not as safe as gold, Avacta shares should be seen as a safe haven right now. War in Ukraine will not impact AVA6k progress.

However, this is absolutely nuts from Putin ..

Did NATO really pose a threat to Russia? Putin is taking about Denazifying Ukraine!!? This is likely to be the start of some very turbulent years for Europe / world. Difficult to see how NATO does not retaliate under these circumstances. The west will back Ukrainian forces operating in Ukraine and eventually I suspect war /atrocities will escalate beyond the borders of Ukraine.

Putin is also now threatening the West with his nukes:
'To anyone who would consider interfering from the outside - if you do, you will face consequences greater than any you have faced in history,’ he said on a television broadcast around 6am Moscow time.

Trading up 20% over the past month which is very likely related to Precision and confirmation of the mechanism of action.

It is worth recalling what AS said during the announcement of the Point license deal;

"The in-house development of AVA6000 Pro-doxorubicin, the first of our pre|CISION chemotherapy prodrugs for which we have recently submitted a CTA filing in the UK to begin clinical trials in 2021, has already generated significant interest and this is highlighted by the agreement with POINT announced today"

The interest has surely increased 10-fold with the announcement of dose escalation...

Industry eyes are very much on Avacta right now - hence AS and team will tread with utmost integrity.

A new TR1 would restore confidence.

However Moderna no longer mentioned on website so could be dropped also.

Think it was ADC.

Avacta could set their sights on the PCR market (for next winter). If they were able to develop a high accuracy test (comparable with PCR) then they would be able to charge a premium.

It would be silly for AS to write off the LFT.. Whether it's Omicron or a new variant, there is VERY likely to be high circulation next winter, leading to pressure on the NHS, leading to a policy that pushes (or forces) mandatory testing before socialising.

There is therefore a very signifcant opportunity in the not to distant future and still plenty time to perfect in time for bulk orders.

This project will be delivered in partnership with Mologic and Tomlinson lab. With mologic now acquired by Gates I'd say its far from over for the Dx division.

Affimers are renewable, recombinant, molecular recognition reagents with diverse applications within molecular and cellular biology, including the study of protein localization, protein function and protein-protein interactions.

Affimer production is highly scalable and reproducible, and combined with their high stability and target specificity, they represent excellent alternative non-antibody tools for the development of molecular detection assays, such as point-of-care LFDs.

Objective

Focusing on selected viruses listed on the World Health Organization (WHO) R&D blueprint (Lassa, Ebola, Rift Valley fever and Crimean-Congo hemorrhagic fever viruses) we will isolate Affimers that bind their respective spike proteins and other relevant proteins such as nucleoproteins, with the aim of developing a multiplexed pathogen detection platform for the diagnosis and differentiation of the corresponding diseases. Development of an Affimer- based diagnostic platform would meet the challenge of the WHO R&D blueprint, and also break the reliance on animal-based antibody production, which is a goal of the BBSRC transformative technologies priority.

The spike-specific Affimers we generate will be also assessed for their ability to neutralize virus infectivity. Structural and functional studies of the spike- Affimer complex will be performed to dissect the molecular basis for neutralization, with the potential to identify sites critical for spike function.

Followed by 'the interview' for PIs.

An orchestrated transfer of wealth from the impatient PI to the patient II?

Would be interested to know how many were squeezed to the point of selling and the amount of shares that have been made available at this heavily discounted price?

Proof will land if/when we receive new TR1.

No doubt it is preferred for AS to have a higher % of II holding shares vs PI, particularly if there is a potential for cheap takeover over the coming months.